NCT07686965尚未招募3 期
Maintenance Therapy With Lisaftoclax Plus Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse: A Multicenter, Open-Label, Randomized Controlled Trial
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 191
- 主要终点
- Disease-Free Survival
研究概览
简要总结
This study evaluates the efficacy and safety of maintenance therapy with lisaftoclax plus azacitidine after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with acute myeloid leukemia (AML) at high risk of relapse.
The main questions this study aims to answer are:
- Does maintenance therapy with lisaftoclax plus azacitidine improve disease-free survival compared with observation alone after allo-HSCT?
- Does maintenance therapy reduce relapse and improve overall survival?
- What adverse events and safety outcomes are associated with this treatment strategy?
Researchers will compare maintenance therapy with lisaftoclax plus azacitidine with observation or best supportive care in patients with AML at high risk of relapse following allo-HSCT.
Participants will:
- Be randomly assigned in a 2:1 ratio to receive either maintenance therapy with lisaftoclax plus azacitidine or observation.
- Receive study treatment for up to 12 cycles or undergo observation according to the study assignment.
- Undergo regular follow-up assessments, disease monitoring, and safety evaluations after transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following criteria to be eligible for enrollment in this study:
- •Diagnosed with acute myeloid leukemia (AML), excluding acute promyelocytic leukemia, according to the WHO 2022 classification, and without FLT3-ITD or FLT3-TKD mutations.
- •Presence of at least one of the following high-risk features:
- •1) Adverse-risk AML according to the ELN 2022 risk classification; 2) Refractory AML; 3) Relapsed AML; 4) Persistent measurable residual disease positivity prior to transplantation; 5) Secondary AML transformed from myelodysplastic syndrome or myeloproliferative neoplasm.
- •3. Undergoing first allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- •4. Stable hematologic recovery, defined as: Absolute neutrophil count ≥ 1.0 × 10⁹/L without G-CSF support; and Platelet count ≥ 50 × 10⁹/L without platelet transfusion within 7 days prior to randomization.
- •5. Age ≥18 years and ≤75 years.
- •Eastern Cooperative Oncology Group performance status of 0-
- •Ability to provide written informed consent before initiation of any study procedures.
- •8. Written informed consent may be provided by the participant or an authorized immediate family member in accordance with local regulations.
排除标准
- •Participants meeting any of the following criteria will be excluded from the study:
- •Evidence of disease relapse or impending relapse prior to randomization after transplantation, as determined by morphologic assessment or flow cytometry.
- •Active or uncontrolled acute graft-versus-host disease (aGVHD) requiring systemic immunosuppressive therapy.
- •Uncontrolled active infection requiring systemic antibacterial, antifungal, or antiviral therapy within 7 days prior to enrollment.
- •Moderate or severe hepatic impairment, as defined by the Child-Pugh classification.
- •Severe renal impairment, defined as creatinine clearance <30 mL/min (calculated using the Cockcroft-Gault formula) or requirement for dialysis.
- •Pregnancy, or unwillingness/inability to use adequate contraception during the study treatment period.
- •Psychiatric disorders or other medical conditions that, in the investigator's judgment, would interfere with compliance with study treatment, monitoring, or study procedures.
结局指标
主要结局
Disease-Free Survival
时间窗: 2 years
Disease status (including relapse) and survival outcomes will be evaluated for the assessment of disease-free survival (DFS). DFS is defined as the time from randomization to the first occurrence of relapse or death from any cause. Prespecified subgroup analyses will be conducted according to pre-transplant measurable residual disease (MRD) status (MRD-positive vs. MRD-negative) to assess the consistency of treatment effects across MRD subgroups.
次要结局
- Cumulative Incidence of Relapse(2 years)
- Overall Survival(2 years.)
- Cumulative Incidence of Pre-emptive Therapy.(2 years)
- Cumulative Incidence of Non-Relapse Mortality(2-years.)
- Treatment-Related Adverse Events(From initiation of maintenance therapy to 30 days after last dose of study drug.)
研究者
相似试验
尚未招募
2 期
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaWMNCT07459608Henan Cancer Hospital75
尚未招募
2 期
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyMantle Cell Lymphoma (MCL)NCT07684950Henan Cancer Hospital45
尚未招募
4 期
"Efficacy and Safety of Linaclotide in Chronic Constipation"Chronic ConstipationNCT07431957Md Mehedi Shahriar90
招募中
1 期
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia PatientsAcute Myeloid LeukemiaNCT07303660Lomond Therapeutics Holdings, Inc.66
进行中（未招募）
3 期
Lisaftoclax (APG-2575) 在既往接受布鲁顿氏酪氨酸激酶（ BTK ）抑制剂治疗的慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤患者中进行的临床研究（GLORA 研究）慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤CTR20260077苏州亚盛药业有限公司